Aplicação dos critérios diagnósticos do lúpus eritematoso sistêmico em pacientes com hanseníase multibacilar

INTRODUÇÃO: O lupus eritematoso sistêmico (LES) é uma doença inflamatória crônica que acomete múltiplos órgãos ou sistemas, não apresenta manifestação clínica patognomônica ou teste laboratorial sensível e específico o suficiente para um diagnóstico específico. Para o diagnóstico, são utilizados os critérios propostos pelo Colégio Americano de Reumatologia (ACR), modificados em 1997. A presença de quatro ou mais critérios tem sensibilidade e especificidade de 96%. Porém, esses critérios para o LES podem ter especificidade mais baixa em regiões endêmicas para doenças infecciosas crônicas, como o Brasil, endêmico para hanseníase, que pode apresentar manifestações clínico-laboratoriais semelhantes. MÉTODOS: Foi realizado um estudo de prevalência, onde foram aplicados os critérios de LES, nos pacientes com diagnóstico recente de hanseníase multibacilar, que deram entrada no ambulatório de hanseníase da Clínica Dermatológica da Universidade Federal de Pernambuco (UFPE) durante o período da coleta de dados, além de calculada a especificidade e o número de falso-positivos nesse grupo. RESULTADOS: Foram incluídos 100 pacientes. As prevalências de alguns dos critérios de LES foram elevadas. Os critérios com maior prevalência foram o eritema malar (44%), a artrite (23%), a fotossensibilidade (29%), a linfopenia (19%) e a presença dos anticorpos antifosfolípides, incluídos no critério imunológico (20%). A especificidade encontrada (84%) foi menor do que a atribuída aos critérios em 1997 pelo ACR. CONCLUSÕES: Doenças presentes em nosso meio, como a hanseníase nas formas multibacilares, mimetizam o quadro clínico-laboratorial do LES, o que deve deixar o médico atento à realidade das doenças infecciosas locais antes de afirmar um diagnóstico definitivo de LES.

Tumor primário de pulmão simulando doença de Alzheimer: relato de caso

RESUMO Retratamos o relato de um homem de 61 anos que apresentava um glioblastoma multiforme em região do giro têmporo-occipital lateral esquerdo que rechaça cranialmente o hipocampo e o corno temporal do ventrículo lateral correspondente. Não havia sinais e sintomas neurológicos e o quadro clínico lembrava a demência de Alzheimer. Havia comprometimento de memória e alterações comportamentais com duração de três meses. Foram afastadas inicialmente outras causas de demência rapidamente progressivas e a ressonância magnética revelou a etiologia tumoral dos sintomas neuropsiquiátricos. Foi submetido à bateria de testes neuropsicométricos com pontuação compatível com doença de Alzheimer (DA). Em razão de extensa área de edema, foi introduzida dexametasona com reversão completa dos sintomas neuropsiquiátricos iniciais e a repetição da bateria neuropsicológica mostrou melhora acentuada em todos os testes. Optou-se por tratamento conservador, após biópsia por agulha, com evolução para óbito em cinco meses.

Resultados comparativos das reações intra-dermicas com antígenos de bacilos ácido-alcool-resistentes (Leprolinas "Souza-Araújo") e emulsão de lepromas (Lepromina): (Primeira Nota)

Em 20 portadores de Lepra, internados na Colônia de São Roque, Paraná, 13 dos quais eram da forma lepromatosa e os 7 restantes da forma nervosa pura ou tuberculoide, o autor estudou a reação intradérmica de antigenos bacilares (Leprolinas Souza-Araujo 1, 1a, 3, 5, 5a), comparativamente com as reações produzidas, ao mesmo tempo, com antígeno lepromatoso (Emulsão de lepromas, lepromina). Observou o seguinte: 1.° - Que a lepromina, comportou-se como habitualmente, isto é, negativa nos lepromatosos e ositiva nos nervosos e tuberculoides e sempre mais intensa ao fim da quarta semana. 2.° - Que as leprolinas provocam reações, que o autor não conclui serem positivas ou negativas no sentido imunológico da expressão em virtude de estar estudando-as neste sentido, nos leprotomatosos e tuberculoides, mas, sempre mais intensas entre a 1.ª e 2.ª semanas, diminuindo de intensidade na 3.ª e desaparecendo ou quase desaparecendo ao fim da quarta semana: nódulos, nódulos-eritema, ulcerações. 3.° - Que nestas reações houve destruição de tecidos, pois a presença tardia de cicatrizes, mesmo quando não houve ulceração, mostra êste fato. 4.° - Que as inoculações das lepromina, não trouxeram nenhum inconveniente a saúde dos paciente; embora um deles tenha apresentado nos primeiros dias leve reação geral; outro, intensa fusão de suas lesões nodulars de lepra e, dois outros, a chamada Reação leprótica.

Akt fosforila FoxG1 en cèl·lules de glioma

En un treball recent s’ha descrit l’amplificació del gen del factor de transcripció FoxG1, homòleg de l'oncogen víric aviar Qin, en mostres de meduloblastoma, un tipus de tumor cerebral que representa el 20% dels tumors cerebrals infantils malignes (Adesina et al.¸2007). El tumor cerebral més freqüent i agressiu en l’adult és el glioma, especialment la seva forma més maligna: el glioblastoma multiforme (glioma de grau IV segons la classificació de l'OMS). En aquest treball hem estudiat l'expressió proteica del factor de transcripció FoxG1, homòleg de l'oncogen víric aviar Qin, en mostres de glioma. Vam analitzar 15 mostres de glioma, detectant FoxG1 en 9 d’elles, i amb diferents nivells d’expressió. Intentant aprofundir en el coneixement de la funció i la regulació de FoxG1, vam estudiar si FoxG1 podia ser fosforilat. Vam detectar, tant per assaig cinasa com per espectrometria de masses, que FoxG1 és un substracte directe de la cinasa Akt, el principal efector de la via de PI3K (phosphoinositide 3-kinase). En la línia cel•lular de glioblastoma U373MG, vam observar que Akt endogen fosforila FoxG1 en un pèptid situat a l’extrem C-terminal del domini forkhead. Aquesta fosforilació és contrarestada per un inhibidor farmacològic de PI3K. Al contrari del que passa en FoxO on la fosforilació per Akt inhibeix l’activitat de FoxO promovent la seva exportació del nucli, la fosforilació de FoxG1 per Akt no promou cap canvi en la seva localització subcel•lular, i FoxG1 es manté nuclear. Actualment estem estudiant els efectes biològics de la fosforilació de FoxG1 per Akt.

La "troisième quête" du Jésus de l'histoire

Il est toujours tentant de diviser l'histoire de la recherche en époques, surtout lorsqu'un groupe ou une tendance s'en fait le repère avec la « troisième quête », fût-ce au prix de pratiques exégétiques et de présupposés méthodologiques pour le moins discutables (par ex. avec le « Jesus Seminar »). Divers modèles et figures du Christ surgissent de cette quête multiforme (Jésus philosophe, cynique itinérant, sapiential, homme de l'Esprit, prophète de la restauration d'Israël, militant du changement social...), ce qui ne suffit pourtant pas à jeter le soupçon sur tous les auteurs ou sur la totalité de leurs travaux (Crossan, Sanders, Theissen et Horsley) dont certains, par leur connaissance du milieu juif contemporain et des mouvements historiques, éclairent singulièrement le contexte politique dans lequel s'inscrit le destin du Christ. Témoignant d'une « relative cohérence », la « troisième quête », par l'usage des sources (y compris apocryphes), la question de l'eschatologie et la valorisation de la judéité de Jésus, ravive la question de l'enjeu théologiquement fort de la quête du Jésus historique.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306).

BACKGROUND: Cilengitide is a selective integrin inhibitor that is well tolerated and has demonstrated biologic activity in patients with recurrent malignant glioma. The primary objectives of this randomized phase 2 trial were to determine the safety and efficacy of cilengitide when combined with radiation and temozolomide for patients with newly diagnosed glioblastoma multiforme and to select a dose for comparative clinical testing. METHODS: In total, 112 patients were accrued. Eighteen patients received standard radiation and temozolomide with cilengitide in a safety run-in phase followed by a randomized phase 2 trial with 94 patients assigned to either a 500 mg dose group or 2000 mg dose group. The trial was designed to estimate overall survival benefit compared with a New Approaches to Brain Tumor Therapy (NABTT) Consortium internal historic control and data from the published European Organization for Research and Treatment of Cancer (EORTC) trial EORTC 26981. RESULTS: Cilengitide at all doses studied was well tolerated with radiation and temozolomide. The median survival was 19.7 months for all patients, 17.4 months for the patients in the 500 mg dose group, 20.8 months for patients in the 2000 mg dose group, 30 months for patients who had methylated O6-methylguanine-DNA methyltransferase (MGMT) status, and 17.4 months for patients who had unmethylated MGMT status. For patients aged ≤70 years, the median survival and survival at 24 months was superior to what was observed in the EORTC trial (20.7 months vs 14.6 months and 41% vs 27%, respectively; P = .008). CONCLUSIONS: Cilengitide was well tolerated when combined with standard chemoradiation and may improve survival for patients newly diagnosed with glioblastoma multiforme regardless of MGMT methylation status. The authors concluded that, from an efficacy and safety standpoint, future trials of this agent in this population should use the 2000 mg dose. Cancer 2012. © 2012 American Cancer Society.

EZH2 is essential for glioblastoma cancer stem cell maintenance.

Overexpression of the polycomb group protein enhancer of zeste homologue 2 (EZH2) occurs in diverse malignancies, including prostate cancer, breast cancer, and glioblastoma multiforme (GBM). Based on its ability to modulate transcription of key genes implicated in cell cycle control, DNA repair, and cell differentiation, EZH2 is believed to play a crucial role in tissue-specific stem cell maintenance and tumor development. Here, we show that targeted pharmacologic disruption of EZH2 by the S-adenosylhomocysteine hydrolase inhibitor 3-deazaneplanocin A (DZNep), or its specific downregulation by short hairpin RNA (shRNA), strongly impairs GBM cancer stem cell (CSC) self-renewal in vitro and tumor-initiating capacity in vivo. Using genome-wide expression analysis of DZNep-treated GBM CSCs, we found the expression of c-myc, recently reported to be essential for GBM CSCs, to be strongly repressed upon EZH2 depletion. Specific shRNA-mediated downregulation of EZH2 in combination with chromatin immunoprecipitation experiments revealed that c-myc is a direct target of EZH2 in GBM CSCs. Taken together, our observations provide evidence that direct transcriptional regulation of c-myc by EZH2 may constitute a novel mechanism underlying GBM CSC maintenance and suggest that EZH2 may be a valuable new therapeutic target for GBM management.

Characterization of metabolites in infiltrating gliomas using ex vivo &supl;H high-resolution magic angle spinning spectroscopy.

Gliomas are routinely graded according to histopathological criteria established by the World Health Organization. Although this classification can be used to understand some of the variance in the clinical outcome of patients, there is still substantial heterogeneity within and between lesions of the same grade. This study evaluated image-guided tissue samples acquired from a large cohort of patients presenting with either new or recurrent gliomas of grades II-IV using ex vivo proton high-resolution magic angle spinning spectroscopy. The quantification of metabolite levels revealed several discrete profiles associated with primary glioma subtypes, as well as secondary subtypes that had undergone transformation to a higher grade at the time of recurrence. Statistical modeling further demonstrated that these metabolomic profiles could be differentially classified with respect to pathological grading and inter-grade conversions. Importantly, the myo-inositol to total choline index allowed for a separation of recurrent low-grade gliomas on different pathological trajectories, the heightened ratio of phosphocholine to glycerophosphocholine uniformly characterized several forms of glioblastoma multiforme, and the onco-metabolite D-2-hydroxyglutarate was shown to help distinguish secondary from primary grade IV glioma, as well as grade II and III from grade IV glioma. These data provide evidence that metabolite levels are of interest in the assessment of both intra-grade and intra-lesional malignancy. Such information could be used to enhance the diagnostic specificity of in vivo spectroscopy and to aid in the selection of the most appropriate therapy for individual patients.

The Rare Cancer Network: achievements from 1993 to 2012.

The Rare Cancer Network (RCN), founded in 1993, performs research involving rare tumors that are not common enough to be the focus of prospective study. Over 55 studies have either been completed or are in progress.The aim of the paper is to present an overview of the 30 studies done through the RCN to date, organized by disease site. Five studies focus on breast pathology, including sarcoma, lymphoma, phyllodes tumor, adenoid cystic carcinoma, and ductal carcinoma in situ in young women. Three studies on prostate cancer address prostatic small cell carcinoma and adenocarcinoma of young and elderly patients. Six studies on head and neck cancers include orbital and intraocular lymphoma, mucosal melanoma, pediatric nasopharyngeal carcinoma, olfactory neuroblastoma, and mucosa-associated lymphoid tissue lymphoma of the salivary glands. There were 4 central nervous system studies on patients with cerebellar glioblastoma multiforme, atypical and malignant meningioma, spinal epidural lymphoma and myxopapillary ependymoma. Outside of these disease sites, there is a wide variety of other studies on tumors ranging from uterine leiomyosarcoma to giant cell tumors of the bone. The studies done by the RCN represent a wide range of rare pathologies that were previously only studied in small series or case reports. With further growth of the RCN and collaboration between members our ability to analyze rare tumors will increase and result in better understanding of their behavior and ultimately help direct research that may improve patient outcomes.

L'image de Paul dans les Actes des apôtres

(Résumé de l'ouvrage) Deuxième volet de l'oeuvre de Luc, le livre des Actes des Apôtres fait aujourd'hui l'objet de multiples travaux où se croisent enquêtes historiennes, analyses littéraires, questions théologiques. Pour son XXe congrès (Angers, août 2003), l'ACFEB a souhaité participer au débat. Ce volume en rassemble les contributions principales. Odile Flichy commence par dresser un panorama des recherches en cours : renouvellement de l'approche historique, lectures narratives, liens avec le judaïsme. Puis Roselyne Dupont-Roc reprend le problème de la double tradition textuelle du livre. Marie-Françoise Baslez situe le « monde des Actes » dans la littérature et la culture de l'époque. Jean-Pierre Lémonon, relisant Actes 18, 18 - 19, 7, examine les différents courants chrétiens qui marquent Éphèse au Ier siècle. Daniel Marguerat montre comment le récit de Luc dessine Paul comme une « figure identitaire » du christianisme. Michel Quesnel se risque à une analyse rhétorique des discours d'apologie de Paul (Ac 22 et 26). Rémi Gounelle débat des relations entre les foisonnants Actes apocryphes des Apôtres et les Actes des Apôtres canoniques. Enfin deux exemples de réception contemporaine du livre des Actes des Apôtres sont proposés : Laurent Villemin traite de son influence sur l'ecclésiologie du concile Vatican II et Carlos Mesters raconte la lecture qu'en font les « communautés ecclésiales de base » au Brésil. Au terme de ce parcours multiforme, les éditeurs n'ont qu'un souhait : que les lecteurs puissent, comme Théophile, « vérifier la solidité des enseignements [qu'ils ont] reçus » !

Karl Barth

Karl Barth (1886-1968) est sans nul doute l'un des géants de la théologie chrétienne du XXe siècle, toutes confessions confondues. À l'instar de ses plus prestigieux modèles - un saint Augustin, un Luther notamment -, c'est dans le corps à corps avec les Écritures saintes, singulièrement avec l'épître de Paul aux Romains, qu'il s'est forgé une conception originale de la pensée chrétienne et qu'il a bouleversé la situation religieuse et théologique de son temps. « Révolutionnaire » dans sa manière de vouloir congédier les théologies libérales du XIXe siècle et de contester en son principe toute forme de complicité du christianisme avec la monde profane ou même avec la modernité, le jeune Barth, celui des années 20, s'est peu à peu transformé en un imposant professeur de dogmatique et en un auteur universellement admiré, étudié, discuté, critiqué. Sa monumentale « Kirchliche Dogmatik », publiée de 1932 à 1968, inachevée, est devenue une référence, aussi bien à l'intérieur du protestantisme que pour le catholicisme romain, comme l'a montré son influence croissante sur des auteurs comme Balthasar, Bouillard et Küng et sur un certain nombre de Pères conciliaires à Vatican II. Le propos de cet ouvrage est de rompre avec les clichés et les idées reçues qui entourent la plupart du temps l'oeuvre multiforme de Barth. Barth y apparaît en permanente recherche, ouvert aux enjeux de la culture et de la société civile, en dialogue critique, certes, mais également très réceptif avec les courants de la modernité et en prise avec l'actualité politique - contre la guerre en 1918, contre le nazisme en 1933-1945, contre la bombe atomique et l'impérialisme américain à la fin de sa vie. L'éthique - individuelle, mais aussi sociale et politique - joue une place centrale dans sa pensée, elle est loin de se réduire à un simple appendice de la dogmatique. Un survol très large de la réception internationale de Barth permet de mesurer l'écho intellectuel et oecuménique considérable de cette théologie en mouvement. Le choix de textes proposé à la fin de l'ouvrage mêle des passages devenus classiques à des aperçus dérangeants et détonnants de l'existence théologique, éthique, politique et culturelle de Barth.

Annular erythematous papules in the neckline.

A 45-year-old woman with personal history of hypertension presented with an erythematous lesion in the neckline for a year and with a progressive growth. A physical examination revealed an annular lesion with erythematous papules in the edge. Histological exam showed phagocytosis of elastic fibers by multinucleated cells compatible with annular elastolytic giant-cell granuloma. The patient did not present any other associated systemic manifestation. Treatment with tacrolimus 0.1 percent ointment was prescribed with a very good response after two months.

Erythema Nodosum as Azathioprine Hypersensitivity Reaction in a Patient with Bullous Pemphigoid.

A 65-year-old woman with bullous pemphigoid presented with fever and several red-purple nodular subcutaneous lesions on both lower legs 1 week after starting treatment with azathioprine (AZA). Biopsy of a skin nodule was compatible with erythema nodosum (EN) and hypersensitivity reaction to AZA was suspected. AZA was subsequently discontinued, observing complete remission of fever and EN within 2 weeks. This case highlights the importance of recognizing EN as a possible manifestation of hypersensitivity reaction to AZA.

Comparativa de dues eines de software pel desenvolupament de classificadors d'espectroscòpia de ressonància magnètica nuclear de tumors cerebrals humans

En aquest treball s’ha fet una avaluació comparativa dels resultats que es poden obtenir amb el software SpectraClassifier 1.0 (SC) desenvolupat al nostre grup de recerca, comparant‐lo amb l’SPSS, un programa estadístic informàtic estàndard, en un problema de classificació de tumors cerebrals humans amb dades d’espectroscopia de ressonància magnètica de protó (1H‐ERM). El interès d’aquesta avaluació comparativa radica en la documentació dels resultats obtinguts amb els dos sistemes quan en la correcció dels resultats obtinguts, així com ponderar la versatilitat i usabilitat dels dos paquets de software per a una aplicació concreta d’interès al treball del GABRMN. Per a aquest treball s’han utilitzat dades provinents de dos projecte europeus multicèntrics (INTERPRET i eTumour) en els quals vam participar. Les classes tumorals utilitzades (d’un total de 217 pacients) han sigut les majoritàries des del punt de vista epidemiològic: glioblastoma multiforme, metàstasi, astrocitomes de grau II, ligodendrogliomes de grau II, oligoastrocitomes de grau II i meningiomes de baix grau. Amb les dades d’aquests pacients s’han dissenyat classificadors basats en l’anàlisi discriminant lineal (LDA), s’han avaluat amb diferents mètodes matemàtics i s’han testat amb dades independents. Els resultats han estat satisfactoris, obtenint amb l’SC resultats més robusts amb dades independents respecte la classificació realitzada per l’SPSS.

Perifollicular erythema as a trichoscopy sign of progression in frontal fibrosing alopecia.

INTRODUCTION Frontal fibrosing alopecia (FFA) in an entity characterized by the recession of the frontotemporal hairline (FTHL) with alopecic scarring change. In recent years there are numerous articles discussing the usefulness of dermoscopy for the clinical diagnosis of different types of scarring alopecia. MATERIALS AND METHODS We value 79 patients diagnosed with FFA, evaluating some trichoscopical findings described as typical for FFA: Absence of follicular opening, follicular hyperkeratosis, follicular plugs and erythema. RESULTS In a population of 79 women, 100% showed no follicular opening, 72.1% follicular hyperkeratosis, 66.3% perifollicular erythema and 44.8% follicular plugs. Thus, 100% of patients had at least one of the dermoscopic elements described as suggestive of FFA, 53% two of them, 45% three and 27%, all those elements. Perifollicular erythema was present in 95% of cases in which the disease was active. CONCLUSIONS We consider that the presence of perifollicular erythema will be a direct marker of FFA activity.